AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Argenica Therapeutics Ltd

0.250

-0.020-7.41%

Volume:403.67K

Turnover:98.44K

Market Cap:32.11M

PE:-4.45

High:0.270

Open:0.260

Low:0.220

Close:0.270

52wk High:0.885

52wk Low:0.190

Shares:128.46M

Float Shares:91.53M

Volume Ratio:1.41

T/O Rate:0.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.056

EPS(LYR):-0.056

ROE:-67.68%

ROA:-35.03%

PB:4.44

PE(LYR):-4.45

Loading ...

Overview Company News Filings

BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition

Argenica Therapeutics Ltd-Non-Executive Director Retirement

THOMSON REUTERS

New Results From Argenica Therapeutics' ARG-007 Second Phase Trial Show 'Encouraging' Signs, Euroz Hartleys Says

MT Newswires Live

Argenica Therapeutics ARG-007 Phase 2 Trial Shows Strong Safety, Efficacy in High-Risk Group, Euroz Hartleys Says

MT Newswires Live

BRIEF-Argenica Therapeutics Seeks Trading Halt

Argenica Therapeutics - Seeks Trading Halt Pending Announcement on Phase 2 Arg-007 Stroke Trial Results

THOMSON REUTERS

Argenica Therapeutics Ltd - FY Loss Attributable a$7.2 Mln

THOMSON REUTERS

Argenica Therapeutics - FY Revenues From Ordinary Activities a$3.7 Mln

THOMSON REUTERS

Argenica Therapeutics Receives Full Clinical Hold Letter from FDA Regarding Investigational New Drug Application

MT Newswires Live

Argenica Therapeutics Ltd-Argenica Appoints Vice President of Regulatory Affairs

THOMSON REUTERS

A 5% Reduction in Brain Cell Injury Volume Significant for Argenica's Acute Ischemic Stroke Treatment Candidate, Euroz Hartleys Says

MT Newswires Live

Cleansing Notice-AGN.AX

Application for quotation of securities - AGN-AGN.AX

BUZZ-Australia's Argenica Therapeutics rises on funding from federal government

BUZZ-Australia's Argenica Therapeutics tumbles as FDA halts stroke drug application

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AGN.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGN.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AGN.AU\",,,,,undefined,":{"symbol":"AGN.AU","market":"AU","secType":"STK","nameCN":"Argenica Therapeutics Ltd","latestPrice":0.25,"timestamp":1764911520000,"preClose":0.27,"halted":0,"volume":403666,"delay":0,"nameEN":"Argenica Therapeutics Ltd","floatShares":91529130,"shares":128456712,"eps":-0.056226,"marketStatus":"Market Closed","change":-0.02,"latestTime":"12-05 16:12:00 AEDT","open":0.26,"high":0.27,"low":0.22,"amount":98436,"amplitude":0.185185,"askPrice":0.26,"askSize":46309,"bidPrice":0.24,"bidSize":14150,"shortable":3,"etf":0,"ttmEps":-0.056226,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1765148400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.27,"openAndCloseTimeList":[[1764889200000,1764910800000]],"volumeRatio":1.4068017295414357,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AGN.AU\",,,,,undefined,":{"symbol":"AGN.AU","floatShares":91529130,"roa":"-35.03%","roe":"-67.68%","lyrEps":-0.056226,"volumeRatio":1.4068017295414357,"shares":128456712,"dividePrice":0,"high":0.27,"amplitude":0.185185,"preClose":0.27,"low":0.22,"week52Low":0.19,"pbRate":"4.44","psRate":"9.99","week52High":0.885,"institutionHeld":0,"latestPrice":0.25,"committee":-0.531914,"eps":-0.056226,"divideRate":0,"volume":403666,"delay":0,"ttmEps":-0.056226,"open":0.26,"prevYearClose":0.63,"prevWeekClose":0.215,"prevMonthClose":0.215,"prevQuarterClose":0.26,"fiveDayClose":0.215,"twentyDayClose":0.27,"sixtyDayClose":0.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGN.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGN.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGN.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588507442","title":"BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2588507442","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588507442?lang=en_us&edition=fundamental","pubTime":"2025-12-04 11:05","pubTimestamp":1764817526,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition** Shares of Australia's Argenica Therapeutics AGN.AX surge as much as 34.1% to A$0.295, their highest since November 3** Biotech f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL6N3XA06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2582496253","title":"Argenica Therapeutics Ltd-Non-Executive Director Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2582496253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582496253?lang=en_us&edition=fundamental","pubTime":"2025-11-12 13:49","pubTimestamp":1762926574,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE4DZW6N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2575334275","title":"New Results From Argenica Therapeutics' ARG-007 Second Phase Trial Show 'Encouraging' Signs, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2575334275","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575334275?lang=en_us&edition=fundamental","pubTime":"2025-10-15 11:00","pubTimestamp":1760497239,"startTime":"0","endTime":"0","summary":"Latest results from Argenica Therapeutics' (ASX:AGN) second phase trial of neuroprotective drug candidate ARG-007 in acute ischemic stroke showed \"encouraging\" signs of functional improvement across c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AGN.AU","BK4539","LENZ","BK4007","BK7096"],"gpt_icon":0},{"id":"2564299713","title":"Argenica Therapeutics ARG-007 Phase 2 Trial Shows Strong Safety, Efficacy in High-Risk Group, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2564299713","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564299713?lang=en_us&edition=fundamental","pubTime":"2025-09-04 15:25","pubTimestamp":1756970704,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics  phase 2 trial of ARG-007 showed strong safety and a meaningful efficacy signal in a key high-risk subgroup, materially de-risking the program and supporting partnering potential, Euroz Hartleys said in a note on Thursday.The company shared phase 2 results showing ARG-007 was safe but did not reduce infarct volume overall in acute ischemic stroke patients.It further added that, in a pre-specified subgroup with slow collateral blood flow, which includes about 30% of participants and represents a third of large vessel occlusion strokes, ARG-007 reduced brain injury by 15%.The firm shared that despite missing broader efficacy goals, ARG-007 showed a meaningful effect in a pre-specified high-risk subgroup and has a strong safety profile supporting a planned phase 2 trial before moving to phase 3.The firm has issued a speculative buy recommendation for Argenica Therapeutics with a per-share target price of AU$1.40, which is currently under review.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGN.AU","BK7096","LENZ","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2564868323","title":"BRIEF-Argenica Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2564868323","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564868323?lang=en_us&edition=fundamental","pubTime":"2025-09-01 07:02","pubTimestamp":1756681355,"startTime":"0","endTime":"0","summary":"BRIEF-Argenica Therapeutics Seeks Trading Halt Sept 1 (Reuters) - Argenica Therapeutics Ltd AGN.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PHASE 2 ARG-007  STROKE TRIAL RESULTSFurther company coverage: AGN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nFWN3UN002:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2564683288","title":"Argenica Therapeutics - Seeks Trading Halt Pending Announcement on Phase 2 Arg-007  Stroke Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2564683288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564683288?lang=en_us&edition=fundamental","pubTime":"2025-09-01 07:02","pubTimestamp":1756681334,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nFWN3UN002:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2562608845","title":"Argenica Therapeutics Ltd -  FY Loss Attributable a$7.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562608845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562608845?lang=en_us&edition=fundamental","pubTime":"2025-08-28 15:06","pubTimestamp":1756364771,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UK011:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2562088437","title":"Argenica Therapeutics - FY Revenues From Ordinary Activities a$3.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562088437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562088437?lang=en_us&edition=fundamental","pubTime":"2025-08-28 15:06","pubTimestamp":1756364771,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UK011:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2559632936","title":"Argenica Therapeutics Receives Full Clinical Hold Letter from FDA Regarding Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2559632936","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559632936?lang=en_us&edition=fundamental","pubTime":"2025-08-14 11:50","pubTimestamp":1755143439,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics  received a full clinical hold letter from the US Food and Drug Administration  on the reasons for the imposed clinical hold and the information required to lift the hold regarding its investigational new drug application, enable clinical trials of the ARG-007 drug candidate in acute ischaemic stroke in the US, according to a Thursday Australian bourse filing.The regulator requested additional information to ensure that the proposed trial dosing for a US trial can be achieved safely in humans, and the firm plans to use its phase two acute ischaemic stroke trial safety data, which will be available in September, as part of its response.The FDA also requested Argenica to conduct three additional in vitro cell culture studies with clinical research organizations to address identified gaps in data. It also asked the firm to include more detail on the phase one data in the investigational brochure.The firm's shares fell 1% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4007","AGN.AU","BK4539","BK7096"],"gpt_icon":0},{"id":"2557317283","title":"Argenica Therapeutics Ltd-Argenica Appoints Vice President of Regulatory Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2557317283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557317283?lang=en_us&edition=fundamental","pubTime":"2025-08-06 06:15","pubTimestamp":1754432155,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nTUE3KMQBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2553291383","title":"A 5% Reduction in Brain Cell Injury Volume Significant for Argenica's Acute Ischemic Stroke Treatment Candidate, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2553291383","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553291383?lang=en_us&edition=fundamental","pubTime":"2025-07-23 14:13","pubTimestamp":1753251195,"startTime":"0","endTime":"0","summary":"A 5% to 10% reduction in the volume of brain cell injury would be considered clinically and commercially meaningful for Argenica Therapeutics'  lead treatment candidate, ARG-007, which is being developed as a neuroprotective therapy for acute ischemic stroke, Euroz Hartleys said in a note on Wednesday.It is currently in a phase two trial in acute ischemic stroke patients with large vessel occlusion who have undergone endovascular thrombectomy. Top-line results are expected in the third quarter.The firm added that the literature suggests that even a 1.6% reduction could be considered clinically meaningful.Euroz Hartleys has a speculative buy rating for the firm with a price target of AU$1.40.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2550351685","title":"Cleansing Notice-AGN.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550351685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550351685?lang=en_us&edition=fundamental","pubTime":"2025-07-09 15:05","pubTimestamp":1752044703,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX6V850R","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASX1L6FMC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2550858316","title":"Application for quotation of securities - AGN-AGN.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550858316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550858316?lang=en_us&edition=fundamental","pubTime":"2025-07-09 15:02","pubTimestamp":1752044526,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX1vd384","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASX7HvkwZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2544197161","title":"BUZZ-Australia's Argenica Therapeutics rises on funding from federal government","url":"https://stock-news.laohu8.com/highlight/detail?id=2544197161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544197161?lang=en_us&edition=fundamental","pubTime":"2025-06-20 08:44","pubTimestamp":1750380272,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Argenica Therapeutics rises on funding from federal government** Shares of Argenica Therapeutics AGN.AX rise as much as 2.1% to A$0.735 to hit highest level since June 11; last up 0.7%** Biotechnology co gets federal government funding up to A$1.5 million  to advance later stage clinical trial of ARG-007 being developed to treat stroke patients** Stock up ~15% this year, including the day's move","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nL6N3SN01F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2542546703","title":"BUZZ-Australia's Argenica Therapeutics tumbles as FDA halts stroke drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2542546703","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542546703?lang=en_us&edition=fundamental","pubTime":"2025-06-10 09:24","pubTimestamp":1749518658,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Argenica Therapeutics tumbles as FDA halts stroke drug application** Biotech firm Argenica Therapeutics shares AGN.AX fall 10.8% to A$0.7, lowest level since May 1** Stock poised for weakest session since early April, if trends sustain** U.S. FDA holds co's Investigational New Drug Application, finding its data \"inadequate\" for clinical trials of acute ischaemic stroke  drug** Co says it will provide additional data to the FDA** AIS patients suffer from decreased blood flow to the brain** Trading volume at more than 113,000 shares vs 30-day avg of around 100,000 shares** Stock up 11.1% YTD, including current session's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nL6N3SD02B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AGN.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}